Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease
Phase 2
Terminated
- Conditions
- Crohn Disease
- Interventions
- Drug: PlaceboDrug: BIBR 796 BS, 5 mgDrug: BIBR 796 BS, 20 mg
- First Posted Date
- 2014-08-06
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 284
- Registration Number
- NCT02209792
Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses Oral BIRB 796 BS in Healthy Human Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: BIBR 796 BSOther: high fat standardized breakfast
- First Posted Date
- 2014-08-05
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 64
- Registration Number
- NCT02208856
Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
- First Posted Date
- 2014-08-05
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT02208843
- Locations
- 🇷🇴
Sf. Nectarie Oncology Center, Craiova, Craiova, Romania
🇷🇸Institute for Oncol & Radiol of Serbia, Clinic f. Med. Onco., Belgrade, Serbia
🇹🇭King Chulalongkorn Memorial Hospital, Bangkok, Thailand
Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02206659
Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse® in Korean Patients With Acute Myocardial Infarction
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 987
- Registration Number
- NCT02206646
Safety, Tolerability and Pharmacokinetics of Increasing Repeated Doses of BIIF 1149 BS in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIIF 1149 BS - single rising doseDrug: Placebo
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT02203487
Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma
Phase 1
Completed
- Conditions
- Melanoma
- Interventions
- Biological: BIBW2 component BBiological: BIBW2 component A
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 49
- Registration Number
- NCT02203864
Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: hMAb BIWA 4
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 9
- Registration Number
- NCT02204059
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
Phase 1
Completed
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 120
- Registration Number
- NCT02204072
- Locations
- 🇪🇸
Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain
🇪🇸Hospital Ramón y Cajal, Madrid, Spain
🇬🇧The Clatterbridge Cancer Centre, Bebington, Wirral, United Kingdom
Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 9
- Registration Number
- NCT02204046